Jeffrey A Baker

US Patent:

20100227335, Sep 9, 2010

Filed:

Mar 5, 2010

Appl. No.:

12/718603

Inventors:

Jeffrey P. Baker - Durham NC, US
Robert L. Cheek - Mebane NC, US
Eric P. Dixon - Cary NC, US
Timothy J. Fischer - Raleigh NC, US
Steven L. Knapp - Apex NC, US
Stephen G. Simkins - Fuquay-Varina NC, US
Clark M. Whitehead - Apex NC, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

G01N 33/574
C07K 16/18
C12N 5/12
C07K 14/435
C07K 7/08
C07H 21/04
C12P 21/04
G01N 33/53

US Classification:

435 74, 53038826, 5303879, 435346, 530324, 530326, 536 235, 435 7021, 435331, 435 79

Abstract:

Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MMP-7. Monoclonal antibodies having the binding characteristics of an MMP-7 antibody of the invention and monoclonal antibodies that bind to an MMP-7 epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce an MMP-7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed MMP-7 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MMP-7 epitope of a disclosed monoclonal MMP-7 antibody and methods of using these polypeptides in the production of MMP-7 antibodies are also encompassed by the present invention.

US Patent:

20170216845, Aug 3, 2017

Filed:

Jan 10, 2017

Appl. No.:

15/403003

Inventors:

- Franklin Lakes NJ, US
- Raheen, IE
James Nealis - Apex NC, US
Jeffrey P. Baker - Durham NC, US
Mark Dalton - Limerick, IE
John D. DeNuzzio - Monkton MD, US
Emma M. Kelly - Waterford, IE
Mitchell E. Gatesman - Morrisville NC, US

International Classification:

B01L 7/00
B01J 19/00

Abstract:

Enhanced composite liquid cell (CLC) devices and methods of using the same are provided. The devices find use in, among other applications, CLC mediated nucleic acid library generation protocols, e.g., for use in next generation sequencing applications.